Weight-loss drug combo may curb CVD events in obese patients

10/6/2011 | MedPage Today (free registration)

Data on 3,363 overweight and obese patients revealed that those who took a combination of naltrexone and bupropion for a year attained a 0.17% reduction in the predicted 10-year risk of cardiovascular events, compared with a 0.05% reduction in those who had a placebo treatment. Researchers found no significant impact on the predicted risk of ischemic heart disease, cardiovascular mortality or stroke in patients. The findings were presented at the Obesity Society meeting.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA